These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 24255129)

  • 21. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.
    Nathanson D; Ullman B; Löfström U; Hedman A; Frick M; Sjöholm A; Nyström T
    Diabetologia; 2012 Apr; 55(4):926-35. PubMed ID: 22246377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure.
    Wimmer A; Stanek B; Kubecova L; Vitovec J; Spinar J; Yilmaz N; Kos T; Hartter E; Frey B; Pacher R
    Jpn Heart J; 1999 May; 40(3):321-34. PubMed ID: 10506854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis.
    Teerlink JR; Davison BA; Cotter G; Maggioni AP; Sato N; Chioncel O; Ertl G; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Edwards C; Senger S; Teichman SL; Nielsen OW; Voors AA; Metra M
    Eur J Heart Fail; 2020 Feb; 22(2):315-329. PubMed ID: 31886953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serelaxin and acute heart failure.
    Tietjens J; Teerlink JR
    Heart; 2016 Jan; 102(2):95-9. PubMed ID: 26603680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
    Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
    Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study.
    Cotter G; Voors AA; Prescott MF; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Milo O; Hua TA; Qian M; Severin TM; Teerlink JR; Metra M; Davison BA
    Eur J Heart Fail; 2015 Nov; 17(11):1133-43. PubMed ID: 26333529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double-blinded, randomized, placebo-controlled, interventional study.
    Barton P; Garcia J; Kouatli A; Kitchen L; Zorka A; Lindsay C; Lawless S; Giroir B
    Chest; 1996 May; 109(5):1302-12. PubMed ID: 8625683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.
    Snowdon VK; Lachlan NJ; Hoy AM; Hadoke PW; Semple SI; Patel D; Mungall W; Kendall TJ; Thomson A; Lennen RJ; Jansen MA; Moran CM; Pellicoro A; Ramachandran P; Shaw I; Aucott RL; Severin T; Saini R; Pak J; Yates D; Dongre N; Duffield JS; Webb DJ; Iredale JP; Hayes PC; Fallowfield JA
    PLoS Med; 2017 Feb; 14(2):e1002248. PubMed ID: 28245243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pulmonary arterial compliance and pulmonary hemodynamic effects of Serelaxin in a sheep model.
    Schiffner R; Reiche J; Schmidt M; Jung C; Walther S; Irintchev A; Bischoff SJ
    Clin Hemorheol Microcirc; 2017; 66(3):219-229. PubMed ID: 28482627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design of the RELAXin in acute heart failure study.
    Ponikowski P; Metra M; Teerlink JR; Unemori E; Felker GM; Voors AA; Filippatos G; Greenberg B; Teichman SL; Severin T; Mueller-Velten G; Cotter G; Davison BA
    Am Heart J; 2012 Feb; 163(2):149-55.e1. PubMed ID: 22305830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure.
    Grantham JA; Borgeson DD; Burnett JC
    Am J Physiol; 1997 Apr; 272(4 Pt 2):R1077-83. PubMed ID: 9140004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study.
    Beermann B; Nyquist O; Höglund C; Jacobsson KA; Näslund U; Jensen-Urstad M
    Eur J Clin Pharmacol; 1993; 45(3):241-6. PubMed ID: 8276048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure.
    Remme WJ; van der Ent M; Bartels GL; van Schelven D; van Hoogenhuyze DC; Krauss XH; Kruijssen HA; Storm CJ
    Cardiovasc Drugs Ther; 1996 May; 10(2):137-44. PubMed ID: 8842505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additive haemodynamic effects of piroximone and prostacyclin in severe chronic heart failure.
    Albo C; Saal JP; Lellouche D; Habbal R; Benvenuti C; Deleuze P; Loisance D; Castaigne A; Dubois-Randé JL
    Eur Heart J; 1994 Apr; 15(4):528-33. PubMed ID: 8070481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.
    Gheorghiade M; Greene SJ; Filippatos G; Erdmann E; Ferrari R; Levy PD; Maggioni A; Nowack C; Mebazaa A;
    Eur J Heart Fail; 2012 Sep; 14(9):1056-66. PubMed ID: 22713287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serelaxin, recombinant human relaxin-2, for heart failure patients: A systematic review and meta-analysis.
    Yu L; Cao L; Sun J; Li Z; Yao F; Zhou Y
    Medicine (Baltimore); 2018 Jun; 97(25):e11010. PubMed ID: 29923986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serelaxin: insights into its haemodynamic, biochemical, and clinical effects in acute heart failure.
    Hernandez AV
    Eur Heart J; 2014 Feb; 35(7):410-2. PubMed ID: 24277752
    [No Abstract]   [Full Text] [Related]  

  • 38. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
    Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A
    Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.
    Díez J
    Am J Cardiovasc Drugs; 2014 Aug; 14(4):275-85. PubMed ID: 24590581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction.
    Gheorghiade M; Greene SJ; Ponikowski P; Maggioni AP; Korewicki J; Macarie C; Metra M; Grzybowski J; Bubenek-Turconi SI; Radziszewski W; Olson A; Bueno OF; Ghosh A; Deckelbaum LI; Li LY; Patel AR; Koester A; Konstam MA
    Eur J Heart Fail; 2013 Jun; 15(6):679-89. PubMed ID: 23471413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.